These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23372646)

  • 1. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
    Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
    PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
    Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
    Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
    Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
    Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
    Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
    Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
    World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL12-γ in primary tumors drives breast cancer metastasis.
    Ray P; Stacer AC; Fenner J; Cavnar SP; Meguiar K; Brown M; Luker KE; Luker GD
    Oncogene; 2015 Apr; 34(16):2043-51. PubMed ID: 24909174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
    Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
    Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
    Hall JM; Korach KS
    Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
    Yoshida D; Koketshu K; Nomura R; Teramoto A
    J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.